Diligence memo · auto-generated · as of July 2, 2026

Eldec Pharmaceuticals, Inc.

Eldec Pharmaceuticals, Inc. looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Eldec Pharmaceuticals, Inc. operates in Pharmaceuticals, based in CHAPEL HILL.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Eldec Pharmaceuticals, Inc. has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $200K on 2026-02-11.

Most recent recorded round closed around 2026-02-11.

Valuation (modeled)modeled

Provath models Eldec Pharmaceuticals, Inc. at approximately $351K (range $112K–$724K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.24× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 5 mo ago; this sector typically re-raises about every 13 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 5% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 0% of those peers.

Closest niche peers: Fedora Pharmaceuticals Inc., PRG FlowChem, Inc., Adora Animal Health Corp, ABLi Therapeutics, Inc., NextEvo, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.